This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Xarelto
  • /
  • Oral Direct Factor Xa Inhibitor Rivaroxaban in Pat...
Clinical trial

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Read time: 1 mins
Last updated:1st Mar 2007

This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for efficacy with a study treatment duration of 3, 6 or 12 months in patients with confirmed acute symptomatic DVT without symptomatic PE (Einstein-DVT).


Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
Enrollment: 3449
Study Start Date: March 2007
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)

Arms:
-  Experimental:
Rivaroxaban (Xarelto, BAY59-7939)
-  Active Comparator: Enoxaparin/VKA

Category Value
Study start date 2007-03-01

View full details